Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

PHASE3RecruitingINTERVENTIONAL
Enrollment

6,150

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Peripheral Arterial DiseaseAtherosclerosis of ExtremitiesInflammation
Interventions
DRUG

Colchicine 0.5 MG Oral Tablet

"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."

DRUG

Colchicine-Placebo

Colchicine-Placebo tablet

Trial Locations (14)

Unknown

RECRUITING

University of Calgary, Peter Lougheed Centre Vascular Clinic, Calgary

RECRUITING

University of Alberta, Mazankowski Heart Institute, Edmonton

RECRUITING

London Health Sciences Centre, London

RECRUITING

Vascular Health Bronte, Oakville

RECRUITING

Corcare Cardiovascular Research Inc., Scarborough Village

RECRUITING

Niagara Health System, St. Catharines

RECRUITING

Sunnybrook Research Institute, Toronto

RECRUITING

CIUSSS du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Cœur-de-Montréal, Montreal

RECRUITING

University Hospital Basel, Angiology, Basel

RECRUITING

HFR Fribourg, Fribourg

RECRUITING

Hôpitaux Universitaires de Genève, Geneva

RECRUITING

University Hospital Zurich, Clinic of Angiology, Zurich

L8L 2X2

RECRUITING

Hamilton General Hospital, Hamilton

G5L 3N2

RECRUITING

Centre intégré de santé et de services sociaux du Bas-Saint-Laurent, Rimouski

All Listed Sponsors
lead

Population Health Research Institute

OTHER